Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats

Journal of Veterinary Medical Science

Volumn 69, Issue 12, 2007, Pages 1271-1276

  Kaneshige, Tatsuo ^a   Saida, Yuuto ^a   Tanaka, Ryou ^a   Soda, Aiko ^a   Fukushima, Akiko ^a   Ida, Nobutaka ^b   Takenaka, Masahiko ^c   Yamane, Yoshihisa ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

^c Takenaka Animal Hospital   (Japan)

Author keywords

Beraprost sodium; Dahl rat; Echocardiography; Hypertension; Myocardial fibrosis

Indexed keywords

BERAPROST; DRUG DERIVATIVE; PROSTACYCLIN; VASODILATOR AGENT;

ANIMAL; ARTICLE; CARDIOMYOPATHY; DAHL SALT SENSITIVE RAT; DRUG ADMINISTRATION; ENDOCARDIUM; FIBROSIS; HEART FAILURE; HEART FUNCTION TEST; HEART VENTRICLE; LONGEVITY; PATHOLOGY; RAT;

ANIMALS; CARDIOMYOPATHIES; DRUG ADMINISTRATION SCHEDULE; ENDOCARDIUM; EPOPROSTENOL; FIBROSIS; HEART FAILURE; HEART FUNCTION TESTS; HEART VENTRICLES; LONGEVITY; RATS; RATS, INBRED DAHL; VASODILATOR AGENTS;

RATTUS;

EID: 38149111717     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.69.1271     Document Type: Article

References (31)

1. Akiba, T., Miyazaki, M. and Toda, N. 1986. Vasodilator actions of K-100, a new prostaglandin I2 analogue. Br. J. Pharmacol. 89: 703-711.
2. Barst, R.J., McGoon, M., McLaughlin, V., Tapson, V., Rich, S., Rubin, L., Wasserman, K., Oudiz, R., Shapiro, S., Robbins, I.M., Channick, R., Badesch, D., Rayburn, B.K., Flinchbaugh, R., Sigman, J., Arneson, C. and Jeffs, R. 2003. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41: 2119-2125.
3. Bayorh, M.A., Ganafa, A.A., Socci, R.R., Silvestrov, N. and Abukhalaf, I.K. 2004. The role of oxidative stress in saltinduced hypertension. Am. J. Hypertens. 17: 31-36.
4. Conrad, C.H., Brooks, W.W., Hayes, J.A., Sen, S., Robinson, K.G. and Bing, O.H. 1995. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91: 161-170.
5. Devereux, R.B. and Reichek, N. 1977. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55: 613-618.
6. Fink, A.N., Frishman, W.H., Azizad, M. and Agarwal, Y. 1999. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Heart Dis. 1: 29-40.
7. Fisher, D.C., Sahn, D.J., Friedman, M.J., Larson, D., Valdes-Cruz, L.M., Horowitz, S., Goldberg, S.J. and Allen, H.D. 1983. The mitral valve orifice method for noninvasive two-dimensional echo Doppler determinations of cardiac output. Circulation 67: 872-877.
8. Galie, N., Manes, A. and Branzi, A. 2003. Prostanoids for pulmonary arterial hypertension. Am. J. Respir. Med. 2: 123-137.
9. Hirano, T., Yamori, Y., Kanai, N., Umetsu, T. and Nishio, S. 1992. The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke. Mol. Chem. Neuropathol. 17: 91-102.
10. Huntsman, L.L., Stewart, D.K., Barnes, S.R., Franklin, S.B., Colocousis, J.S. and Hessel, E.A. 1983. Noninvasive Doppler determination of cardiac output in man. Clin. Validation Circulation 67: 593-602.
11. Kawaguchi, M., Hay, I., Fetics, B. and Kass, D.A. 2003. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107: 714-720.
12. Kushiro, M., Shikata, K., Sugimoto, H., Shikata, Y., Miyatake, N., Wada, J., Miyasaka, M. and Makino, H. 1998. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int. 53: 1314-1320.
13. Nakayama, T., Hironaga, T., Ishima, H., Maruyama, T., Masubuchi, Y. and Kokubun, S. 2004. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostaglandins. Leukot. Essent. Fatty Acids. 70: 491-494.
14. Nishimura, R.A. and Tajik, A.J. 1994. Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization. Prog. Cardiovasc. Dis. 36: 309-342.
15. Nishio, S., Matsuura, H., Hattori, M., Endoh, T., Yamada, N., Hirano, T., Murai, T., Miyao, Y., Kanai, T. and Umetsu, T. 1989. Cardiovascular effects of beraprost sodium (TRK-100), a prostacyclin analogue in the dog. Nippon Yakurigaku Zasshi 94: 351-361.
16. Nishio, S. and Kurumatani, H. 2001. Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue. Nippon Yakurigaku Zasshi 117: 123-130.
17. Ono, F., Nagaya, N., Kyotani, S., Oya, H., Nakanishi, N. and Miyatake, K. 2003. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ. J. 67: 375-378.
18. Ono, K., Masuyama, T., Yamamoto, K., Doi, R., Sakata, Y., Nishikawa, N., Mano, T., Kuzuya, T., Takeda, H. and Hori, M. 2002. Echo doppler assessment of left ventricular function in rats with hypertensive hypertrophy. J. Am. Soc. Echocardiogr. 15: 109-117.
19. Otsuki, M., Goya, K. and Kasayama, S. 2005. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vasc. Health. Risk. Manag. 1: 209-215.
20. Paramothayan, N.S., Lasserson, T.J., Wells, A.U. and Walters, E.H. 2002. Prostacyclin for pulmonary hypertension. Cochrane Database Syst. Rev. 2002: CD002994.
21. Parodi, O., De Maria, R., Oltrona, L., Testa, R., Sambuceti, G., Roghi, A., Merli, M., Belingheri, L., Accinni, R., Spinelli, F. and et al. 1993. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation 88: 509-522.
22. Rubin, L.J., Groves, B.M., Reeves, J.T., Frosolono, M., Handel, F. and Cato, A.E. 1982. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66: 334-338.
23. Tomiyama, H., Arai, T., Hirose, K., Koji, Y., Motobe, K., Yambe, M. and Yamashina, A. 2004. Effects of acute administration of beraprost sodium on parameters related to atherosclerotic vascular damage in coronary artery disease. J. Cardiol. 43: 53-58.
24. Uehara, Y., Koga, M. and Takahashi, M. 1995. Determination of cardiac output by echocardiography. J. Vet. Med. Sci. 57: 401-407.
25. Ueno, Y., Okazaki, S., Isogaya, M., Nishio, S., Tanaka, H., Kato, Y. and Shigenobu, K. 1996. Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. Gen. Pharmacol. 27: 101-103.
26. Weber, K.T. and Brilla, C.G. 1991. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865.
27. Weber, K.T., Anversa, P., Armstrong, P.W., Brilla, C.G., Burnett, J.C. Jr, Cruickshank, J.M., Devereux, R.B., Giles, T.D., Korsgaard, N., Leier, C.V. and et, al. 1992. Remodeling and reparation of the cardiovascular system. J. Am. Coll. Cardiol. 20: 3-16.
28. Yamada, M., Sasaki, R., Sato, N., Suzuki, M., Tamura, M., Matsushita, T. and Kurumatani, H. 2002. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur. J. Pharmacol. 449: 167-176.
29. Yamashita, T., Shikata, K., Matsuda, M., Okada, S., Ogawa, D., Sugimoto, H., Wada, J. and Makino, H. 2002. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res. Clin. Pract. 57: 149-161.
30. Yu, H., Gallagher, A.M., Garfin, P.M. and Printz, M.P. 1997. Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression. Hypertension 30: 1047-1053.
31. Zile, M.R. and Brutsaert, D.L. 2002. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105: 1503-1508.